We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+11.56%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$8.44B
AUM Growth
+$1.09B
(+15%)
Cap. Flow
+$577M
Cap. Flow
% of AUM
6.84%
Top 10 Holdings %
Top 10 Hldgs %
15.63%
Holding
838
New
218
Increased
181
Reduced
162
Closed
220
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$123M |
| 2 |
HES
Hess
HES
|
+$115M |
| 3 |
ATVI
Activision Blizzard
ATVI
|
+$108M |
| 4 |
Cencora
COR
|
+$106M |
| 5 |
Microsoft
MSFT
|
+$101M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$108M |
| 2 |
Analog Devices
ADI
|
+$105M |
| 3 |
Keysight
KEYS
|
+$101M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$82.2M |
| 5 |
Booking.com
BKNG
|
+$58.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37.55% |
| 2 | Technology | 28% |
| 3 | Industrials | 9.43% |
| 4 | Energy | 7.74% |
| 5 | Consumer Discretionary | 5.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Mirum Pharmaceuticals
MIRM
$6.38B
| $8.48M | 0.1% |
327,818
-196,062
| -37% | -$5.21M |
|
227
Harmony Biosciences
HRMY
$2.06B
| $8.45M | 0.1% |
+240,216
| New | +$8.29M |
|
228
Curtiss-Wright
CW
$27.6B
| $8.37M | 0.1% |
+45,558
| New | +$7.77M |
|
229
Best Buy
BBY
$18B
| $8.3M | 0.1% |
101,316
+22,380
| +28% | +$1.67M |
|
230
IBM
IBM
$213B
| $8.24M | 0.1% |
+61,601
| New | +$7.95M |
|
231
Walmart Inc
WMT
$881B
| $8.19M | 0.1% |
156,276
+59,343
| +61% | +$2.99M |
|
232
Shake Shack
SHAK
$2.61B
| $8.19M | 0.1% |
+105,326
| New | +$6.77M |
|
233
Lowe's Companies
LOW
$119B
| $8.18M | 0.1% |
36,234
-18,532
| -34% | -$3.85M |
|
|
PYCR
234
DELISTED
Paycor HCM, Inc. Common Stock
PYCR
| $8.14M | 0.1% |
343,923
-21,136
| -6% | -$493K |
|
235
Ardelyx
ARDX
$1.23B
| $8.11M | 0.1% |
2,392,862
+1,427,863
| +148% | +$5.85M |
|
236
Viatris
VTRS
$20.5B
| $8.11M | 0.1% |
+812,500
| New | +$7.76M |
|
237
BlackRock Capital Allocation Term Trust
BCAT
$1.66B
| $8.01M | 0.09% |
525,011
+316,242
| +151% | +$4.75M |
|
|
CEM
238
DELISTED
ClearBridge MLP and Midstream Fund Inc.
CEM
| $7.83M | 0.09% |
225,745
+56,639
| +33% | +$1.86M |
|
239
Darden Restaurants
DRI
$23.6B
| $7.82M | 0.09% |
+46,808
| New | +$7.35M |
|
240
Charter Communications
CHTR
$17.2B
| $7.8M | 0.09% |
21,239
-38,638
| -65% | -$13.2M |
|
241
Arcutis Biotherapeutics
ARQT
$3.24B
| $7.7M | 0.09% |
807,750
+112,075
| +16% | +$1.24M |
|
242
Omnicom Group
OMC
$21.7B
| $7.7M | 0.09% |
+80,880
| New | +$7.51M |
|
243
Biomea Fusion
BMEA
$86.8M
| $7.5M | 0.09% |
341,673
| – | – |
|
|
VERV
244
DELISTED
Verve Therapeutics
VERV
| $7.4M | 0.09% |
394,421
+7,955
| +2% | +$132K |
|
245
KB Home
KBH
$3.45B
| $7.34M | 0.09% |
+141,866
| New | +$6.4M |
|
246
TJX Companies
TJX
$174B
| $7.3M | 0.09% |
86,094
-117,820
| -58% | -$9.29M |
|
247
AMN Healthcare
AMN
$1.28B
| $7.28M | 0.09% |
+66,708
| New | +$6.32M |
|
248
NetEase
NTES
$84.2B
| $7.21M | 0.09% |
+74,587
| New | +$6.74M |
|
249
Elanco Animal Health
ELAN
$12.8B
| $7.14M | 0.08% |
+709,854
| New | +$6.59M |
|
250
Louisiana-Pacific
LPX
$5.15B
| $7.1M | 0.08% |
94,731
+44,151
| +87% | +$2.73M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q2 2023 Portfolio in Review
As of Q2 2023, Woodline Partners held 838 positions worth $8.44B, up 15% from $7.35B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Woodline Partners deployed $577M of net new capital in Q2 2023, opening 218 new positions and adding to 181 existing holdings. Its largest new stake was Hess: 837,083 shares worth $114M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 35% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Keysight, an estimated $101M trimmed.
- Woodline Partners's largest Q2 2023 buy was Hess: 837,083 shares worth $114M.
- Woodline Partners added most to Johnson & Johnson in Q2 2023, an estimated $123M increase.
- Woodline Partners's biggest Q2 2023 reduction was Keysight, cutting an estimated $101M.
- Woodline Partners fully exited Baxter International in Q2 2023, selling an estimated $108M.
- Woodline Partners's ten largest holdings make up 16% of its $8.44B portfolio in Q2 2023.
- Woodline Partners opened 218 new positions and closed 220 in Q2 2023.
- Woodline Partners's portfolio value rose 15% quarter-over-quarter to $8.44B.
Based on Woodline Partners's 13F filing for Q2 2023, filed 14 Aug 2023.